Papadimitriou Ilias, Bakirtzi Katerina, Katoulis Alexander, Ioannides Dimitrios
First Dermatology and Venereology Department, School of Medicine Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, "Attikon" University Hospital, Athens, Greece.
Skin Appendage Disord. 2021 Nov;7(6):439-448. doi: 10.1159/000517806. Epub 2021 Aug 3.
Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.
头皮局限性银屑病在斑块状银屑病患者中很常见，这使得其治疗极具难度。此外，该疾病引起的症状，如脱屑、红斑和瘙痒等，对患者的心理产生重大影响，并使其生活质量显著下降。生物制剂已证明其在缓解症状方面的疗效，即降低银屑病面积和严重程度指数（PASI），并通过降低斑块状银屑病患者的皮肤病生活质量指数（DLQI），为患者提供最佳生活质量。在此，我们试图评估生物制剂和小分子药物在控制症状方面的疗效，以及它们在维持疾病缓解方面的长期能力。
